[go: up one dir, main page]

ATE471373T1 - Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna - Google Patents

Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna

Info

Publication number
ATE471373T1
ATE471373T1 AT98949508T AT98949508T ATE471373T1 AT E471373 T1 ATE471373 T1 AT E471373T1 AT 98949508 T AT98949508 T AT 98949508T AT 98949508 T AT98949508 T AT 98949508T AT E471373 T1 ATE471373 T1 AT E471373T1
Authority
AT
Austria
Prior art keywords
expression
genes
gene
methods
nucleic acid
Prior art date
Application number
AT98949508T
Other languages
English (en)
Inventor
John Harrington
Original Assignee
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co filed Critical Abt Holding Co
Application granted granted Critical
Publication of ATE471373T1 publication Critical patent/ATE471373T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98949508T 1997-09-26 1998-09-25 Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna ATE471373T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94122397A 1997-09-26 1997-09-26
US15964398A 1998-09-24 1998-09-24
PCT/US1998/020094 WO1999015650A1 (en) 1997-09-26 1998-09-25 Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna

Publications (1)

Publication Number Publication Date
ATE471373T1 true ATE471373T1 (de) 2010-07-15

Family

ID=26856150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949508T ATE471373T1 (de) 1997-09-26 1998-09-25 Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna

Country Status (15)

Country Link
EP (1) EP1017803B1 (de)
JP (1) JP5377806B2 (de)
KR (1) KR20010024296A (de)
CN (1) CN100582230C (de)
AT (1) ATE471373T1 (de)
AU (1) AU750025B2 (de)
BR (1) BR9812540A (de)
CA (1) CA2304642C (de)
DE (1) DE69841723D1 (de)
DK (1) DK1017803T3 (de)
HK (1) HK1027375A1 (de)
IL (2) IL135242A0 (de)
NO (1) NO20001497L (de)
NZ (1) NZ504185A (de)
WO (1) WO1999015650A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6740503B1 (en) 1997-09-26 2004-05-25 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
CA2364267A1 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
EP2308974A3 (de) 1999-10-14 2011-08-10 Clontech Laboratories Inc. Aus Anthozoa abgeleitete Chrom-/Fluorproteine sowie Verwendungsverfahren dafür
EP1294879B1 (de) 2000-06-28 2008-12-31 Amgen Inc. Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
EP1352060A2 (de) * 2000-10-30 2003-10-15 Novozymes Biotech, Inc. Verfahren zur expression von endogenen genen mittels restriktion enzym-vermittelter integrierung
US7767454B2 (en) 2001-11-02 2010-08-03 Abt Holding Company Methods for mutating genes in cells using insertional mutagenesis
EP1456223B1 (de) 2001-12-19 2009-08-12 The University Of Chicago Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
JP2005536228A (ja) 2002-08-21 2005-12-02 レビビコア， インコーポレイテッド 機能的α−１，３−ガラクトシルトランスフェラーゼのいかなる発現をも欠くブタ動物
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8021833B2 (en) 2003-02-12 2011-09-20 Functional Genetics, Inc. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
DK1734814T3 (en) 2004-03-17 2015-04-07 Revivicor Inc Tissue DERIVED FROM ANIMALS IS MISSING ANY EXPRESSION OF FUNCTIONAL ALPHA-1,3 galactosyltransferase
EP1732944B1 (de) 2004-04-07 2012-09-05 The University of Chicago Monomere, rotfluoreszierende proteine
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
CA2585098C (en) 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
CA2617930A1 (en) 2005-08-09 2007-03-29 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
JP5102833B2 (ja) 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2964910C (en) 2007-04-27 2018-01-09 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
EP2525808A2 (de) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin als behandlungsmittel für männliche fortpflanzungsstörungen
CN102669057B (zh) * 2011-03-18 2014-11-26 上海南方模式生物科技发展有限公司 一种调控动物内源基因表达的遗传修饰方法
KR101948248B1 (ko) * 2011-11-18 2019-02-14 한국생명공학연구원 단백질 발현 미세 조절방법
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
CN106455514A (zh) * 2014-03-14 2017-02-22 希博斯美国有限公司 采用寡核苷酸介导的基因修复提高靶向基因修饰的效率的方法和组合物
JP7175608B2 (ja) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 加齢に伴うフレイルのための治療としてのオステオカルシン
WO2019222359A1 (en) * 2018-05-15 2019-11-21 Duke University Systems and methods for genetic manipulation of akkermansia species

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
KR100233781B1 (ko) * 1989-11-06 1999-12-01 스테펜 에이. 쉐어윈 동종 재조합을 이용하는 단백질 제조방법
US5204939A (en) * 1989-12-14 1993-04-20 Fujitsu Limited Rule base processing system and rule evaluation control method therein
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
CA2364267A1 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes

Also Published As

Publication number Publication date
AU750025B2 (en) 2002-07-11
HK1027375A1 (en) 2001-01-12
DE69841723D1 (de) 2010-07-29
NZ504185A (en) 2003-02-28
BR9812540A (pt) 2001-12-26
JP2003535564A (ja) 2003-12-02
KR20010024296A (ko) 2001-03-26
NO20001497L (no) 2000-05-25
AU9581698A (en) 1999-04-12
CA2304642A1 (en) 1999-04-01
EP1017803A4 (de) 2002-01-09
NO20001497D0 (no) 2000-03-22
CN100582230C (zh) 2010-01-20
EP1017803B1 (de) 2010-06-16
IL135242A (en) 2011-06-30
CA2304642C (en) 2014-11-18
JP5377806B2 (ja) 2013-12-25
IL135242A0 (en) 2001-05-20
DK1017803T3 (da) 2010-08-23
EP1017803A1 (de) 2000-07-12
WO1999015650A1 (en) 1999-04-01
WO1999015650A9 (en) 2000-09-08
CN1280615A (zh) 2001-01-17

Similar Documents

Publication Publication Date Title
ATE471373T1 (de) Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna
Johnson et al. Inhibition of luciferase expression in transgenic Aedes aegypti mosquitoes by Sindbis virus expression of antisense luciferase RNA
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
Pekosz et al. Influenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence
Jaag et al. An unusual internal ribosomal entry site of inverted symmetry directs expression of a potato leafroll polerovirus replication-associated protein
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE404679T1 (de) Neue expressionsvektoren
WO2000049162A3 (en) Compositions and methods for non-targeted activation of endogenous genes
Garber et al. Induction of Drosophila RNA polymerase III gene expression by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) is mediated by transcription factor IIIB
WO2002002760A3 (en) 25869, a human carboxylesterase and uses thereof
AU2002320301A1 (en) Novel pgc-1 isoforms and uses therefor
Christophides et al. Expression and function of the Drosophila melanogaster ADH in male Ceratitis capitata adults: a potential strategy for medfly genetic sexing based on gene‐transfer technology
Borovsky et al. Juvenile hormone affects the splicing of Culex quinquefasciatus early trypsin messenger RNA
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
DE60130465D1 (de) Mutierte muskelspezifische enhancer
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
Golik et al. The Rieske FeS protein encoded and synthesized within mitochondria complements a deficiency in the nuclear gene
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
Choy et al. Nuclear factors from expressing tissues interact in vitro with a rat α-2u globulin gene intron
Wiklund ESTROGEN INDUCED PITUITARY GROWTH AND DNA SYNTHESIS: GENETIC DIFFERENCES IN RESPONSE TO CHRONIC TREATMENT IN THE RAT.
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
WO2001074854A3 (en) 32449, a putative human transporter and uses thereof
WO2002029037A3 (en) 57800, a novel human cadherin and uses therefor
WO2002008394A3 (en) 23430, a novel human ubiquitin hydrolase family member and uses therefor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties